See more : Gränges AB (publ) (GRNG.ST) Income Statement Analysis – Financial Results
Complete financial analysis of Zymergen Inc. (ZY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Zymergen Inc., a leading company in the Chemicals – Specialty industry within the Basic Materials sector.
- Clean Vision Corporation (CLNV) Income Statement Analysis – Financial Results
- Pennar Industries Limited (PENIND.NS) Income Statement Analysis – Financial Results
- Pigeon Corporation (7956.T) Income Statement Analysis – Financial Results
- Tracsis plc (TRCS.L) Income Statement Analysis – Financial Results
- Celebrity Fashions Limited (CELEBRITY.BO) Income Statement Analysis – Financial Results
Zymergen Inc. (ZY)
About Zymergen Inc.
Zymergen Inc. design, develop, and commercialize microbes, molecules, and materials. It offers an automation solution comprising reconfigurable automation carts, a modular hardware building blocks that allow for assembly of work cells customized for the particular needs of a lab; and automation control software, a cloud-based software used to control integrated automation systems. It serves electronics, packaging, healthcare, agriculture, and other industries. Zymergen Inc. was incorporated in 2013 and is based in Emeryville, California. As of October 19, 2022, Zymergen Inc. operates as a subsidiary of Ginkgo Bioworks Holdings, Inc.
| Metric | 2021 | 2020 | 2019 |
|---|---|---|---|
| Revenue | 16.74M | 13.28M | 15.42M |
| Cost of Revenue | 69.72M | 84.82M | 102.64M |
| Gross Profit | -52.98M | -71.53M | -87.22M |
| Gross Profit Ratio | -316.42% | -538.50% | -565.67% |
| Research & Development | 159.12M | 90.85M | 50.72M |
| General & Administrative | 83.01M | 60.08M | 61.25M |
| Selling & Marketing | 23.65M | 18.63M | 24.14M |
| SG&A | 106.66M | 78.70M | 85.39M |
| Other Expenses | 175.51M | 0.00 | 0.00 |
| Operating Expenses | 265.78M | 169.56M | 136.10M |
| Cost & Expenses | 335.50M | 254.37M | 238.74M |
| Interest Income | 64.00K | 492.00K | 4.92M |
| Interest Expense | 14.71M | 10.96M | 2.94M |
| Depreciation & Amortization | 20.70M | 18.71M | 15.20M |
| EBITDA | -326.33M | -232.58M | -218.65M |
| EBITDA Ratio | -1,949.08% | -1,750.80% | -1,418.08% |
| Operating Income | -347.03M | -241.09M | -237.11M |
| Operating Income Ratio | -2,072.68% | -1,814.88% | -1,537.80% |
| Total Other Income/Expenses | -14.71M | -21.15M | 318.00K |
| Income Before Tax | -361.73M | -262.24M | -236.80M |
| Income Before Tax Ratio | -2,160.51% | -1,974.13% | -1,535.74% |
| Income Tax Expense | 51.00K | -49.00K | 8.00K |
| Net Income | -361.79M | -262.19M | -236.80M |
| Net Income Ratio | -2,160.81% | -1,973.76% | -1,535.79% |
| EPS | -4.87 | -2.68 | -2.42 |
| EPS Diluted | -4.87 | -2.68 | -2.42 |
| Weighted Avg Shares Out | 74.31M | 97.94M | 97.94M |
| Weighted Avg Shares Out (Dil) | 74.31M | 97.94M | 97.94M |
Zymergen (ZY) Reports Q1 Loss, Tops Revenue Estimates
Zymergen Reports Preliminary First Quarter 2022 Financial Results
Zymergen (ZY) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Zymergen to Participate in the BofA Securities 2022 Healthcare Conference
10 Top Penny Stocks Cathie Wood ARK Invest Owns, Time To Buy?
Why Shares of Zymergen Are Plunging Today
Zymergen to Report Preliminary First Quarter 2022 Financial Results on May 12, 2022
Zymergen, Inc. (ZY) CEO Jay Flatley on Q4 2021 Results - Earnings Call Transcript
Zymergen Reports Preliminary Fourth Quarter and Full Year 2021 Financial Results
Zymergen to Report Preliminary Fourth Quarter and Full Year 2021 Financial Results on March 22nd, 2022
Source: https://incomestatements.info
Category: Stock Reports